A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent…
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is relatively rare among people with primary sclerosing cholangitis (PSC) who do not have…
A class of medicines called PPAR agonists that modulate genes involved in inflammation and scarring improve biochemical markers of liver function and ease itching in…
E-therapeutics announced positive preclinical toxicology data on ETX-312, its therapy for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver…
Six months of treatment with lanifibranor, Inventiva’s experimental therapy, reduced abnormalities in liver sinusoidal endothelial cells (LSECs) in people with metabolic dysfunction-associated steatohepatitis (MASH),…
Biliary atresia, a rare liver disease affecting infants, may be diagnosed before birth using a novel artificial intelligence (AI) method that analyzes prenatal ultrasound…
Combining the levels of two liver damage markers, obtained from standard blood tests, can accurately discriminate infants with biliary atresia from those without the…
The use of an experimental, one-time gene therapy in a mouse model of Alagille syndrome increased the number of bile ducts — tubes that…
The cumulative healthcare costs for infants with biliary atresia can increase substantially if they undergo their initial treatment, the Kasai surgery, after 2 months…
ACER3, an enzyme involved in the metabolism of fat-like signaling molecules known as ceramides, plays a detrimental role in cholestasis-related liver damage — and,…
